Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Research


Biggest-ever philanthropic gift to diabetes research brings Type 1 cure closer

April 26th 2022

An incredible and unprecedented £50 million investment from the Steve Morgan Foundation, the partnership will fund game-changing type 1 diabetes research that will pave the way to the development of new treatments and a cure (Diabetes UK)

Categories: News, Research
Tags: Type 1 Diabetes

Categories: Research
Tags: Type 1 Diabetes

Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results

September 30th 2021

We have developed a checklist of points we consider most important when reading and interpreting RCT publications (Diabetes Therapy)

Categories: News, Research
Tags: RCT

Categories: Research
Tags: RCT

Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: a tripartite comparison

March 12th 2021

Regulatory authorities using identical trial data made substantially different decisions regarding both safety and efficacy of hypoglycemic drugs. The differences in initial indication wording between Japan and the other authorities suggest that trial data and T2D are interpreted differently in these regions (British Journal of Clinical Pharmacology)

Categories: Cardiovascular, Medication, News, Research
Tags: trials, Type 2 Diabetes

Categories: Cardiovascular, Medication, Research
Tags: trials, Type 2 Diabetes

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes

January 21st 2021

As strategy-driven, head-to-head RCTs comparing SGLT-2i, GLP-1RA, or DPP-4i with metformin (and their combination with metformin) while ensuring glycemic and weight equipoise are unlikely to become available in the future, sharing and analyzing individual-level data from already conducted RCT would help to inform the evidence for the best first-line treatment(s) in subjects with type 2 diabetes and confirm or refute our finding (Diabetes Care)

Categories: News, Research
Tags: DPP-4i, GLP-1RA, metformin, SGLT2 inhibitors

Categories: Research
Tags: DPP-4i, GLP-1RA, metformin, SGLT2 inhibitors

Coded diagnoses from general practice electronic health records are a feasible and valid alternative to self-report to define diabetes cases in research

September 2nd 2020

ICPC-coded diagnoses of DM from general practice electronic health records are a feasible and valid alternative to self-reported diagnoses of DM  (Primary Care Diabetes)

Categories: News, Research
Tags: ICPC-code

Categories: Research
Tags: ICPC-code

Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials

June 2nd 2020

Guidelines for early-onset adult type 2 diabetes are extrapolated predominantly from evidence in older individuals. Strategies to support the participation of individuals with early-onset adult type 2 diabetes in future research are imperative to ensure guidelines for these high-risk individuals are evidence-based (Diabetologia)

Categories: News, Research
Tags: trials, Type 2 Diabetes

Categories: Research
Tags: trials, Type 2 Diabetes

How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?

January 21st 2020

The deeper analysis of data from the well-powered SWITCH studies does support that the new IHSG level 2 definition compared with the previous ADA definition can result in statistically more robust findings when comparing insulins (Diabetes Care)

Categories: News, Research
Tags: hypoglycemia, SWITCH

Categories: Research
Tags: hypoglycemia, SWITCH

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study

April 1st 2019

In large T2D populations within Europe, consistent patterns of representativeness of CVOTs were found when applying the main enrolment criteria. The DECLARE‐TMI 58 trial had the highest representativeness, indicating that it included and examined patients who are most representative of the general T2D patients in the studied countries (Diabetes, Obesity and Metabolism)

Categories: News, Research
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Research
Tags: SGLT2 inhibitors, Type 2 Diabetes

How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population?

December 13th 2018

In large T2D populations from Europe, consistent patterns of representativeness for CVOTs were found when applying main enrollment criteria. DECLARE‐TMI 58 showed the highest representativeness, indicating that it includes and examines patients who are most representative of the general T2D patient in the studied countries (Diabetes, Obesity and Metabolism)

Categories: News, Research
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Research
Tags: SGLT2 inhibitors, Type 2 Diabetes

Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis

November 19th 2018

In contrast to real-world data, there was no evidence of an improvement in all-cause and cardiovascular mortality in type 2 diabetes participants included in control arms of randomised clinical trials across 5 decades. Further studies should investigate whether and how dissimilarities in populations, procedures, and assessments of exposures and outcomes explain the differences between real-world setting and clinical trials (Acta Diabetologica)

Categories: News, Research
Tags: Type 2 Diabetes

Categories: Research
Tags: Type 2 Diabetes

Positive 15-month results with Diamyd® in Type 1 diabetes

September 11th 2018

When all patients have been followed for 15 months in the diabetes trial DIAGNODE-1, where the diabetes vaccine Diamyd® is given directly into the lymph node, a clearly positive and clinically relevant effect is seen in improving the clinical course and maintaining the endogenous insulin production in newly diagnosed type 1 diabetes (Diamyd Medical)

Categories: Research
Tags: lymph node, Type 1 Diabetes

European diabetes research and its funding, 2002–2013

June 21st 2017

The European diabetes burden in disability-adjusted life years increased by one third between 2002 and 2012, but its output of research papers has decreased from 44% to 36% of the world total. This decrease needs to be reviewed in the context of European non-communicable disease research policy (Diabetic Medicine)

Categories: News, Research
Tags: Europe, funding

Categories: Research
Tags: Europe, funding

Stepwise reprogramming of liver cells to a pancreas progenitor state by the transcriptional regulator Tgif2

February 13th 2017

This study uncovers the reprogramming activity of TGIF2 and suggests a stepwise reprogramming paradigm, whereby a ‘lineage-restricted’ dedifferentiation step precedes the identity switch (Nature)

Categories: News, Research
Tags: Pancreas, progenitor, Tgif2

Categories: Research
Tags: Pancreas, progenitor, Tgif2

Hypoglycemia Evaluation and Reporting in Diabetes

January 5th 2017

Importance for the Development of New Therapies

Categories: News, Research
Tags: hypoglycemia

Categories: Research
Tags: hypoglycemia

Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes

December 28th 2016

To determine the clinical trial representation of black or African American people, we reviewed the published data from the seven cardiovascular outcome trials instigated by the 2008 FDA mandate for evaluating cardiovascular risk for new therapies in type 2 diabetes (The Lancet Diabetes & Endocrinology)

Categories: News, Research
Tags: Type 2 Diabetes

Categories: Research
Tags: Type 2 Diabetes

Generation of stem cell-derived β-cells from patients with type 1 diabetes

May 10th 2016

These results show that T1D SC-β cells could potentially be used for the treatment of diabetes, drug screening and the study of β-cell biology (Nature)

Categories: News, Research
Tags: stem cells, Type 1 Diabetes

Categories: Research
Tags: stem cells, Type 1 Diabetes

Brown Adipose Tissue Exhibits a Glucose-Responsive Thermogenic Biorhythm in Humans

March 10th 2016

In this study, we explored the relationship between hBAT and glucose metabolism in a series of whole-body and in vitro studies in humans. We hypothesized that hBAT regulates glucose fluxes and plays a determinative role in whole-body glucose homeostasis (Cell Metabolism)

Categories: News, Research
Tags: brown fat

Categories: Research
Tags: brown fat

Metabolomics and Type 2 Diabetes: Translating Basic Research into Clinical Application

November 9th 2015

The use of metabolomics for predicting T2D comorbidities is gaining momentum, as are our approaches for translating basic metabolomics research into clinical applications. As a result, metabolomics has the potential to enable informed decision-making in the realm of personalized medicine (Journal of Diabetes Research)

Categories: News, Research
Tags: metabolomics, Type 2 Diabetes

Categories: Research
Tags: metabolomics, Type 2 Diabetes

Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project

August 25th 2015

The outstanding results of these dog studies coupled with the positive findings from the in vitro work provide support and confidence to move forward as quickly as possible with the remaining clinical and regulatory work necessary to achieve FDA approval of the enhanced Generex Oral-lyn™ formulation (Generex)

Categories: News, Research
Tags: buccal, insulin

Categories: Research
Tags: buccal, insulin

Productivity of authors in the field of diabetes: bibliographic analysis of trial publications

July 2nd 2015

The past two decades have seen an explosive increase in the number of published clinical trials regarding glucose lowering treatment. Some authors have made a disproportionate contribution to the therapeutic evidence base; one third of the RCT evidence base on glucose lowering drug treatment for diabetes was generated by <1% of authors.(BMJ)

Categories: News, Research
Tags: authors

Categories: Research
Tags: authors
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Boehringer IngelheimNovo NordiskAstraZenecaNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership